3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
44
Neoplasm Metastasis
5
Neoplasms
4
Metastatic Castration-Resistant Prostate Cancer
3
Adenocarcinoma
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasm, Residual
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Fatigue
1
Depression
1
Castration Resistant Metastatic Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Breast Neoplasms
1
Bites and Stings
1
Interventions
mazdutide
1
lime
1
fasudil
1
Tablets
1
Referral and Consultation
1
Ramipril
1
Radiosurgery
1
Metformin
1
Mental Status and Dementia Tests
1
Memantine
1
Health
1
Exercise
1
Acetylcysteine
1
Accidental Falls
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Cognitive Dysfunction
×
enzalutamide
×
90 days
×
Clear all
No trials found.